Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MPS-derived T-cells
- Development stage
- Preclinical
- Lead developer
- Minerva Biotechnologies
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Tumor-Infiltrating Lymphocytes (TILs) → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
MPS-derived T-cells is an experimental cell therapy being developed by Minerva Biotechnologies for the treatment of MUC1*-positive solid tumors. The therapy utilizes T cells generated through the company's proprietary Minimal Protein Surface (MPS) platform, which is designed to produce naive-state stem cells and their derivatives. These T cells are engineered to specifically target MUC1*, the truncated, oncogenic form of the MUC1 protein that functions as a growth factor receptor on the surface of many cancer cells. By focusing on the MUC1* isoform, which is prevalent in over 75% of solid tumors but absent in normal tissues, the therapy aims to provide a highly specific anti-tumor response while minimizing off-target effects on healthy tissues expressing full-length MUC1.
- Other names
- Minerva MUC1* cell therapyMUC1* MPS-derived T-cells
02
Targets
MUC1 (Mucin-1 Antigen)
Beyond the preview
Go deeper on MPS-derived T-cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MPS-derived T-cells.